Published in Neuropharmacology on March 06, 2010
Capsaicin modulates acetylcholine release at the myoneural junction. Eur J Pharmacol (2014) 0.76
Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions. Toxicon (2013) 0.76
Botulinum toxin as a biological weapon: medical and public health management. JAMA (2001) 9.18
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Advantages of the triangularis sterni muscle of the mouse for investigations of synaptic phenomena. J Neurosci Methods (1981) 1.63
Bacterial protein toxins penetrate cells via a four-step mechanism. FEBS Lett (1994) 1.58
Severe botulism after focal injection of botulinum toxin. Neurology (2006) 1.51
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) (2008) 1.37
Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A (2009) 1.26
Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun (Camb) (2006) 1.25
Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache (2003) 1.22
A high-affinity competitive inhibitor of type A botulinum neurotoxin protease activity. FEBS Lett (2002) 1.16
Antagonism of botulinum toxin A-mediated muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps. Toxicon (2000) 1.06
Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle. Toxicon (2001) 1.04
Recovery of mouse neuromuscular junctions from single and repeated injections of botulinum neurotoxin A. J Physiol (2008) 1.04
The role of the synaptic protein snap-25 in the potency of botulinum neurotoxin type A. J Biol Chem (2001) 1.01
The effects of presynaptic calcium channel modulation by roscovitine on transmitter release at the adult frog neuromuscular junction. Eur J Neurosci (2006) 1.00
Identification of an ion channel-forming motif in the primary structure of tetanus and botulinum neurotoxins. FEBS Lett (1992) 0.99
The interaction between aminoquinolines and presynaptically acting neurotoxins. J Pharmacol Exp Ther (1982) 0.94
A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol (1992) 0.90
Effect of 3,4-diaminopyridine on rat extensor digitorum longus muscle paralyzed by local injection of botulinum neurotoxin. Toxicon (1996) 0.90
Antagonism of botulinum toxin-induced muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm preparations. Toxicon (1995) 0.90
Capsaicin protects mouse neuromuscular junctions from the neuroparalytic effects of botulinum neurotoxin a. J Pharmacol Exp Ther (2009) 0.88
Evidence for antibody-catalyzed ozone formation in bacterial killing and inflammation. Science (2002) 2.51
Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol (2007) 2.24
Evidence for ozone formation in human atherosclerotic arteries. Science (2003) 2.22
Revisiting quorum sensing: Discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones. Proc Natl Acad Sci U S A (2004) 2.05
Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule. Science (2008) 1.93
An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A (2007) 1.85
Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett (2006) 1.81
The strange case of the botulinum neurotoxin: using chemistry and biology to modulate the most deadly poison. Angew Chem Int Ed Engl (2008) 1.80
Deeply inverted electron-hole recombination in a luminescent antibody-stilbene complex. Science (2008) 1.79
Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem (2006) 1.79
Hyperglycemia impairs glucose and insulin regulation of nitric oxide production in glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol (2007) 1.78
Structures of Clostridium botulinum Neurotoxin Serotype A Light Chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol (2007) 1.78
Treating cocaine addiction with viruses. Proc Natl Acad Sci U S A (2004) 1.75
Uncharacterized 4,5-dihydroxy-2,3-pentanedione (DPD) molecules revealed through NMR spectroscopy: implications for a greater signaling diversity in bacterial species. Angew Chem Int Ed Engl (2012) 1.55
Fluorescent cocaine probes: a tool for the selection and engineering of therapeutic antibodies. J Am Chem Soc (2005) 1.48
Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand. Biochemistry (2006) 1.48
A vaccine strategy that induces protective immunity against heroin. J Med Chem (2011) 1.47
Vaccination against weight gain. Proc Natl Acad Sci U S A (2006) 1.45
N-(3-oxo-acyl)homoserine lactones signal cell activation through a mechanism distinct from the canonical pathogen-associated molecular pattern recognition receptor pathways. J Biol Chem (2006) 1.42
Glucose, insulin, and leptin signaling pathways modulate nitric oxide synthesis in glucose-inhibited neurons in the ventromedial hypothalamus. Am J Physiol Regul Integr Comp Physiol (2006) 1.41
Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence. Pharmacol Biochem Behav (2009) 1.39
MPZP: a novel small molecule corticotropin-releasing factor type 1 receptor (CRF1) antagonist. Pharmacol Biochem Behav (2007) 1.39
Toward the discovery of potent inhibitors of botulinum neurotoxin A: development of a robust LC MS based assay operational from low to subnanomolar enzyme concentrations. Chem Commun (Camb) (2008) 1.37
Investigations using immunization to attenuate the psychoactive effects of nicotine. Bioorg Med Chem (2004) 1.37
Mechanistic studies of a peptidic GRP78 ligand for cancer cell-specific drug delivery. Mol Pharm (2007) 1.35
Histidine kinases as targets for new antimicrobial agents. Bioorg Med Chem (2002) 1.33
Impact of distinct chemical structures for the development of a methamphetamine vaccine. J Am Chem Soc (2011) 1.31
Synthesis and biological validation of a ubiquitous quorum-sensing molecule. Angew Chem Int Ed Engl (2004) 1.29
The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. ACS Chem Biol (2006) 1.26
A critical evaluation of a nicotine vaccine within a self-administration behavioral model. Mol Pharm (2010) 1.26
Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci U S A (2009) 1.26
Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun (Camb) (2006) 1.25
Dynamic vaccine blocks relapse to compulsive intake of heroin. Proc Natl Acad Sci U S A (2013) 1.24
Essential roles of the acetylcholine receptor gamma-subunit in neuromuscular synaptic patterning. Development (2008) 1.22
Combinatorial antibody libraries from cancer patients yield ligand-mimetic Arg-Gly-Asp-containing immunoglobulins that inhibit breast cancer metastasis. Proc Natl Acad Sci U S A (2004) 1.21
A credit-card library approach for disrupting protein-protein interactions. Bioorg Med Chem (2005) 1.20
Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav (2005) 1.19
Synthesis and structure-activity relationships of second-generation hydroxamate botulinum neurotoxin A protease inhibitors. Bioorg Med Chem Lett (2007) 1.19
Cocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs. Mol Ther (2011) 1.18
A method for the generation of combinatorial antibody libraries using pIX phage display. Proc Natl Acad Sci U S A (2002) 1.18
Interspecies and interkingdom communication mediated by bacterial quorum sensing. Chem Soc Rev (2008) 1.17
Botulinum neurotoxin A protease: discovery of natural product exosite inhibitors. J Am Chem Soc (2010) 1.14
An unexpected switch in the modulation of AI-2-based quorum sensing discovered through synthetic 4,5-dihydroxy-2,3-pentanedione analogues. J Am Chem Soc (2008) 1.14
Aptamer selection by high-throughput sequencing and informatic analysis. Biotechniques (2011) 1.14
Antibody interference with N-acyl homoserine lactone-mediated bacterial quorum sensing. J Am Chem Soc (2006) 1.13
Analysis of epitope information related to Bacillus anthracis and Clostridium botulinum. Expert Rev Vaccines (2008) 1.13
Structural basis for ligand recognition and discrimination of a quorum-quenching antibody. J Biol Chem (2011) 1.13
Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals. J Am Chem Soc (2009) 1.12
A methamphetamine vaccine attenuates methamphetamine-induced disruptions in thermoregulation and activity in rats. Biol Psychiatry (2012) 1.11
Neural aspects of sentence comprehension: syntactic complexity, reversibility, and reanalysis. Cereb Cortex (2009) 1.11
Development of immunopharmacotherapy against drugs of abuse. Curr Drug Discov Technol (2004) 1.10
N-H insertion reactions of primary ureas: the synthesis of highly substituted imidazolones and imidazoles from diazocarbonyls. J Org Chem (2004) 1.09
A molecular link between the active component of marijuana and Alzheimer's disease pathology. Mol Pharm (2006) 1.09
Targeting cell-impermeable prodrug activation to tumor microenvironment eradicates multiple drug-resistant neoplasms. Cancer Res (2006) 1.08
Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1. FEBS Lett (2010) 1.07
Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effects. Neuropsychopharmacology (2011) 1.07
Medicinal chemistry as a conduit for the modulation of quorum sensing. J Med Chem (2010) 1.06
Total synthesis of the depsipeptide FR-901375. J Org Chem (2003) 1.06
Tissue factor-activated coagulation cascade in the tumor microenvironment is critical for tumor progression and an effective target for therapy. Cancer Res (2011) 1.04
Light chain of botulinum neurotoxin serotype A: structural resolution of a catalytic intermediate. Biochemistry (2006) 1.04
Soluble polymers as scaffolds for recoverable catalysts and reagents. Chem Rev (2002) 1.04
Mefloquine enhances nigral gamma-aminobutyric acid release via inhibition of cholinesterase. J Pharmacol Exp Ther (2006) 1.04
Pharmacophore reassignment for induction of the immunosurveillance cytokine TRAIL. Angew Chem Int Ed Engl (2014) 1.03
Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network. Br J Haematol (2011) 1.02
A previously undescribed chemical link between smoking and metabolic disease. Proc Natl Acad Sci U S A (2002) 1.02
Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem (2004) 1.02
Human antibodies against spores of the genus Bacillus: a model study for detection of and protection against anthrax and the bioterrorist threat. Proc Natl Acad Sci U S A (2002) 1.01
A new strategy for improved nicotine vaccines using conformationally constrained haptens. J Am Chem Soc (2003) 1.00
Repositioning of an existing drug for the neglected tropical disease Onchocerciasis. Proc Natl Acad Sci U S A (2010) 1.00
Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol (2006) 0.99
Strategies for longitudinal neuroimaging studies of overt language production. Neuroimage (2009) 0.99
Chirality holds the key for potent inhibition of the botulinum neurotoxin serotype a protease. Org Lett (2010) 0.99
Toward cocaine esterase therapeutics. J Am Chem Soc (2005) 0.99
Bone marrow stroma influences transforming growth factor-beta production in breast cancer cells to regulate c-myc activation of the preprotachykinin-I gene in breast cancer cells. Cancer Res (2004) 0.99
Investigating the effects of a hydrolytically stable hapten and a Th1 adjuvant on heroin vaccine performance. J Med Chem (2012) 0.99
Catalytic antibodies: hapten design strategies and screening methods. Bioorg Med Chem (2004) 0.98
Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine (2013) 0.98
Technological advancements for the detection of and protection against biological and chemical warfare agents. Chem Soc Rev (2007) 0.97
Tandem fluorescent proteins as enhanced FRET-based substrates for botulinum neurotoxin activity. Toxicon (2009) 0.97
Complete reaction cycle of a cocaine catalytic antibody at atomic resolution. Structure (2006) 0.96
Quantitative mass spectrometry identifies drug targets in cancer stem cell-containing side population. Stem Cells (2008) 0.96
Bacterial quorum sensing: a new target for anti-infective immunotherapy. Expert Opin Biol Ther (2008) 0.96
Evidence for the production of trioxygen species during antibody-catalyzed chemical modification of antigens. Proc Natl Acad Sci U S A (2003) 0.96
Investigations into small molecule non-peptidic inhibitors of the botulinum neurotoxins. Toxicon (2009) 0.96
A blue fluorescent antibody-cofactor sensor for mercury. Org Lett (2005) 0.95
An antidote for acute cocaine toxicity. Mol Pharm (2012) 0.95
Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. J Comb Chem (2006) 0.95
Recombinant botulinum neurotoxin A heavy chain-based delivery vehicles for neuronal cell targeting. Protein Eng Des Sel (2010) 0.94
A human single-chain antibody specific for integrin alpha3beta1 capable of cell internalization and delivery of antitumor agents. Chem Biol (2004) 0.94
Revisiting AI-2 quorum sensing inhibitors: direct comparison of alkyl-DPD analogues and a natural product fimbrolide. J Am Chem Soc (2009) 0.94
Synthesis, properties, and reactivity of cocaine benzoylthio ester possessing the cocaine absolute configuration. J Am Chem Soc (2002) 0.94
Botulinum neurotoxin serotype A inhibitors: small-molecule mercaptoacetamide analogs. Bioorg Med Chem (2009) 0.93
Anti-cocaine vaccine based on coupling a cocaine analog to a disrupted adenovirus. CNS Neurol Disord Drug Targets (2011) 0.93
Peptidomimetics and peptide backbone modifications. Mini Rev Med Chem (2002) 0.93
Glycation of the amyloid beta-protein by a nicotine metabolite: a fortuitous chemical dynamic between smoking and Alzheimer's disease. Proc Natl Acad Sci U S A (2003) 0.93